Loss of Interleukin-17RA Expression is Associated with Tumour Progression in Colorectal Carcinoma
| Autor: | Norhafizah Mohtarrudin, Heng Fong Seow, Boon Yean Chai, Noraini Mohd Dusa, Wai Kien Yip |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male Cancer Research Colorectal cancer medicine.medical_treatment Lymph node metastasis Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine medicine Biomarkers Tumor Humans Prognostic biomarker Receptor Receptors Interleukin-17 business.industry Interleukin-17 Interleukin General Medicine Middle Aged medicine.disease Prognosis 030104 developmental biology Cytokine Oncology 030220 oncology & carcinogenesis Cancer research Disease Progression Immunohistochemistry Female Interleukin 17 business Colorectal Neoplasms Follow-Up Studies |
| Zdroj: | Pathology oncology research : POR. 26(4) |
| ISSN: | 1532-2807 |
| Popis: | Interleukin-17 (IL-17) is a pro-inflammatory cytokine found in various cancers. Current evidence indicates that IL-17 plays a vital role in tumour initiation and progression in colorectal carcinoma (CRC) via binding with its receptor, IL-17RA. However, the association between clinicopathological features and presence of IL-17 and IL-17RA protein in primary CRC tissues remains unclear. This study also investigates the difference between the presence of IL-17 and IL-17RA in the paired tumour tissues versus adjacent normal tissues. The presence of IL-17RA and IL-17 protein in primary CRC tissues was determined by immunohistochemistry. Associations between clinicopathological features and IL-17RA and IL-17 immunoreactivity, were analyzed by χ2 tests. We found that both IL-17RA (p = 0.001) and IL-17 (p = 0.025) in tumour cells of primary CRC tissues was significantly lower as compared to adjacent normal tissue. Positive immunoreactivity for IL-17RA and IL-17 were detected in 51.0% and 16.8% of tumour tissues, respectively. Furthermore, negative immunoreactivity of IL-17R was significantly associated with advanced stage according to TNM classifier (p = 0.027), high grade of tumour (p = 0.019), increased depth of tumour invasion (p = 0.023) and vascular invasion (p = 0.039). Positive IL-17 immunoreactivity was associated with advanced stage (p = 0.008) and lymph node metastasis (p = 0.008). Thus, this study suggests that the loss of IL-17RA expression occurs as tumour progresses and this may predict the aggressiveness of tumour whilst expression of IL-17 promotes tumour progression and lymph node metastasis. Thus, loss of IL-17RA could be a useful prognostic biomarker for tumour progression in CRC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink